261 related articles for article (PubMed ID: 20923428)
1. Effects of osmotic-release methylphenidate in attention-deficit/hyperactivity disorder as measured by event-related potentials.
Sawada M; Iida J; Ota T; Negoro H; Tanaka S; Sadamatsu M; Kishimoto T
Psychiatry Clin Neurosci; 2010 Oct; 64(5):491-8. PubMed ID: 20923428
[TBL] [Abstract][Full Text] [Related]
2. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
3. Effect of methylphenidate on auditory event related potential in boys with attention deficit hyperactivity disorder.
Ozdag MF; Yorbik O; Ulas UH; Hamamcioglu K; Vural O
Int J Pediatr Otorhinolaryngol; 2004 Oct; 68(10):1267-72. PubMed ID: 15364497
[TBL] [Abstract][Full Text] [Related]
4. Event-related potentials reflect the efficacy of pharmaceutical treatments in children and adolescents with attention deficit/hyperactivity disorder.
Yamamuro K; Ota T; Iida J; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto N; Tanaka S; Kishimoto T
Psychiatry Res; 2016 Aug; 242():288-294. PubMed ID: 27318633
[TBL] [Abstract][Full Text] [Related]
5. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
6. Effects of methylphenidate in ADHD adults on target evaluation processing reflected by event-related potentials.
Ohlmeier MD; Prox V; Zhang Y; Zedler M; Ziegenbein M; Emrich HM; Dietrich DE
Neurosci Lett; 2007 Sep; 424(3):149-54. PubMed ID: 17723273
[TBL] [Abstract][Full Text] [Related]
7. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
8. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder.
Gormez V; Avery B; Mann H
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2345-9. PubMed ID: 24065228
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder.
Hwang JW; Kim B; Kim Y; Kim TH; Seo WS; Shin DW; Woo YJ; Yoo H; Lee JS; Lee JH; Lim MH; Chung YC; Jung CH; Yoo HK
Hum Psychopharmacol; 2013 Nov; 28(6):600-7. PubMed ID: 24519694
[TBL] [Abstract][Full Text] [Related]
10. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
[TBL] [Abstract][Full Text] [Related]
11. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate.
Kim E; Cheon KA; Joung YS; Kim JY; Song DH
Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917
[TBL] [Abstract][Full Text] [Related]
12. Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation.
Fernández-Jaén A; Fernández-Mayoralas DM; Pardos A; Calleja-Pérez B; Muñoz Jareño N
Adv Ther; 2009 Dec; 26(12):1097-110. PubMed ID: 20082241
[TBL] [Abstract][Full Text] [Related]
13. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
14. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Marcus SC; Wan GJ; Kemner JE; Olfson M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
[TBL] [Abstract][Full Text] [Related]
15. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.
Sinzig J; Döpfner M; Lehmkuhl G; ; Uebel H; Schmeck K; Poustka F; Gerber WD; Günter M; Knölker U; Gehrke M; Hässler F; Resch F; Brünger M; Ose C; Fischer R
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):421-32. PubMed ID: 17822338
[TBL] [Abstract][Full Text] [Related]
16. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
Golubchik P; Kodesh A; Weizman A
Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
[TBL] [Abstract][Full Text] [Related]
17. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
[TBL] [Abstract][Full Text] [Related]
18. The influence of methylphenidate on the power spectrum of ADHD children - an MEG study.
Wienbruch C; Paul I; Bauer S; Kivelitz H
BMC Psychiatry; 2005 Jul; 5():29. PubMed ID: 16042816
[TBL] [Abstract][Full Text] [Related]
19. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study.
Wilens TE; Biederman J; Lerner M;
J Clin Psychopharmacol; 2004 Feb; 24(1):36-41. PubMed ID: 14709945
[TBL] [Abstract][Full Text] [Related]
20. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.
Kim BN; Kim JW; Cummins TD; Bellgrove MA; Hawi Z; Hong SB; Yang YH; Kim HJ; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
J Clin Psychopharmacol; 2013 Jun; 33(3):356-62. PubMed ID: 23609393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
